Catalent Cell & Gene Therapy, Germany
Dr. Thomas Berger is a research scientist at Catalent Pharma Solutions, working on gene editing of induced pluripotent stem cells (iPSCs) and is based at the Duesseldorf site. After completing his Undergraduate degree in Molecular Biomedicine at the University of Bonn, and a Master's degree in Neuroscience from the University of Heidelberg, he pursued his PhD at King's College London from 2018 to 2022, where he used CRISPR to model genetic polymorphisms associated with Depression or Alzheimer's Disease in an iPSC-based model of neurogenesis. Afterwards, he joined Catalent. where he fully focuses on developing efficient GMP-compatible gene editing workflows in iPSCs aiming to accelerate CRISPR-based cell therapies, as well as the generation of iPSC lines with enhanced features such as hypoimmunity.
Friday, July 12, 2024
8:15 AM – 9:45 AM CEST
Friday, July 12, 2024
9:10 AM – 9:20 AM CEST